These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 5451221)

  • 1. Cyclophosphamide toxicity in Ugandan and American patients with malignant lymphoma.
    Brown CH; Ziegler JL; Templeton C; Carbone PP
    Cancer; 1970 Aug; 26(2):462-7. PubMed ID: 5451221
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with Wegener's granulomatosis.
    Dale DC; Fauci AS; Wolff SM
    Arthritis Rheum; 1973; 16(5):657-64. PubMed ID: 4742843
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cytostatic treatment of lymphogranulomatosis. Experiences with ibenzmethyzine, cyclophosphamide and vinblastine sulfate].
    Schubert JC; Martin H
    Munch Med Wochenschr; 1968 Jan; 110(2):97-100. PubMed ID: 5695132
    [No Abstract]   [Full Text] [Related]  

  • 4. [Results of very high cyclophosphamide dosage in 42 patients with solid and lymphoreticular tumors].
    Schubert JC; Ischer M; Hilbert L
    Dtsch Med Wochenschr; 1969 Dec; 94(50):2583-8 passim. PubMed ID: 4187888
    [No Abstract]   [Full Text] [Related]  

  • 5. Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.
    Morgan LR; Harrison EF; Hawke JE; Hunter HL; Costanzi JJ; Plotkin D; Tucker WG; Worrall PM
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):66-70. PubMed ID: 7163813
    [No Abstract]   [Full Text] [Related]  

  • 6. Endotoxin stimulation in patients with lymphoma: correlation with the myelosuppressive effects of alkylating agents.
    DeConti RC; Kaplan SR; Calabresi P
    Blood; 1972 May; 39(5):602-9. PubMed ID: 5067305
    [No Abstract]   [Full Text] [Related]  

  • 7. Etiocholanolone in the evaluation of marrow reserves in patients receiving cytotoxic agents.
    Vogel JM; Kimball HR; Wolff SM; Perry S
    Ann Intern Med; 1967 Dec; 67(6):1226-38. PubMed ID: 4863110
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclophosphamide in the treatment of myelomatosis.
    Choi OS; English A; Hilton JH; Catton GE; Brown MD
    Can Med Assoc J; 1967 Nov; 97(19):1133-9. PubMed ID: 4168247
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclophosphamide treatment of lymphoma during third trimester of pregnancy.
    Hardin JA
    Obstet Gynecol; 1972 Jun; 39(6):850-1. PubMed ID: 5049899
    [No Abstract]   [Full Text] [Related]  

  • 10. [Induction polychemotherapy of non-Hodgkin's lymphomas in children].
    Radulesku GG; Kolygin BA
    Vopr Onkol; 1984; 30(6):33-7. PubMed ID: 6547553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cyclophosphamide and intermediate-dose methotrexate for the treatment of far-advanced Burkitt's lymphoma.
    Brecher ML; Gardner RV; Ettinger LJ; Tebbi CK; Green DM; Freeman AI
    Am J Pediatr Hematol Oncol; 1985; 7(2):117-24. PubMed ID: 3842557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of cyclophosphamide during late pregnancy and early lactation: a case report.
    Durodola JI
    J Natl Med Assoc; 1979 Feb; 71(2):165-6. PubMed ID: 423292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma.
    Lenhard RE; Oken MM; Barnes JM; Humphrey RL; Glick JH; Silverstein MN
    Cancer; 1984 Apr; 53(7):1456-60. PubMed ID: 6697291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study.
    Talley RW; O'Bryan RM; Gutterman JU; Brownlee RW; McCredie KB
    Cancer Chemother Rep; 1973; 57(4):465-71. PubMed ID: 4762440
    [No Abstract]   [Full Text] [Related]  

  • 15. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
    Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
    Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
    Martoni A; Rani P; Ercolino L; Canova N; Pannuti F
    Chemioterapia; 1988 Oct; 7(5):345-9. PubMed ID: 3224403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphology of Burkitt's lymphoma during regression induced by cyclophosphamide.
    Osunkoya BO; Ngu VA; Mottram FC
    Cancer; 1970 Mar; 25(3):505-9. PubMed ID: 5416823
    [No Abstract]   [Full Text] [Related]  

  • 18. Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan.
    Hedley DW; McElwain TJ; Millar JL; Gordon MY
    Lancet; 1978 Nov; 2(8097):966-8. PubMed ID: 81990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected toxicity in patients treated with iphosphamide.
    Van Dyk JJ; Falkson HC; Van der Merwe AM; Falkson G
    Cancer Res; 1972 May; 32(5):921-4. PubMed ID: 4552918
    [No Abstract]   [Full Text] [Related]  

  • 20. Causes of death in patients with burkitt's lymphoma--the role of supportive care in overall management.
    Magrath IT; Semawere C; Nkwocha J
    East Afr Med J; 1974 Sep; 51(9):623-32. PubMed ID: 4434879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.